Executive Summary

As a Chinese healthcare player investing money into the oncology treatment market, Luye Group is seeking to stay ahead of the competition by adding disease screening and in vitro diagnostics to its arsenal, via a major investment into Vela Diagnostics of Singapore. As the window of opportunity closes in, the two are working quickly to bring products to the China market.

Read more at: https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/12/3/luye-builds-china-cancer-diagnosis-capability-via-vela-investment

For further enquiry, please contact Global Product Management, gpm@veladx.com